Supernus Pharmaceuticals (SUPN)
(Delayed Data from NSDQ)
$33.84 USD
-0.14 (-0.41%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $33.84 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$33.84 USD
-0.14 (-0.41%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $33.84 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth B Momentum B VGM
Zacks News
Does Supernus (SUPN) Have the Potential to Rally 28.65% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 28.7% upside potential for Supernus (SUPN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Supernus (SUPN) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of -2.70% and 13.12%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Select Medical (SEM) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of 1.69% and 1.63%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Supernus (SUPN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Supernus (SUPN) stock based on the movements in the options market lately.
Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ahead of Supernus (SUPN) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Supernus (SUPN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Supernus (SUPN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Supernus Pharmaceuticals (SUPN) Lags Q4 Earnings Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of -95.12% and 6.39%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Ahead of Supernus (SUPN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Supernus (SUPN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -1.05% and 74.53%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Supernus (SUPN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Supernus Pharmaceuticals (SUPN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of -323.08% and 8.74%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals (SUPN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Compared to Estimates, Supernus (SUPN) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Supernus Pharmaceuticals (SUPN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of -108.70% and 6.64%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Bausch Health (BHC) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 8% and 6.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of 4.08% and 88.27%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Supernus (SUPN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of 141.67% and 8.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
BridgeBio Pharma (BBIO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -9.52% and 74.54%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals (SUPN) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of -41.10% and 8.15%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals (SUPN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Supernus Pharmaceuticals (SUPN) Misses Q3 Earnings Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of -90.63% and 2.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?